Atezolizumab and Pembrolizumab in Triple-Negative Breast Cancer: A Meta-Analysis
Last Updated: Thursday, November 3, 2022
The approval of anti–PD-L1 drugs, including atezolizumab and pembrolizumab, has expanded the number of treatment regimens available for triple-negative breast cancer. The authors collate evidence of atezolizumab and pembrolizumab as viable therapeutics among patients with TNBC, with PD-L1 subgroups deriving higher benefits.
Advertisement
News & Literature Highlights